High HMGB1 level is associated with poor outcome of septicemic melioidosis

International Journal of Infectious Diseases

Volumn 28, Issue , 2014, Pages 111-116

  Charoensup, Jaruek ^a   Sermswan, Rasana W ^a,b   Paeyao, Arunee ^a   Promakhejohn, Sairavee ^c   Punasee, Sirilak ^d   Chularari, Charanya ^d   Krabkraikaew, Sukunya ^c   Lertanekawattana, Sujet ^c   Wongratanacheewin, Surasakdi ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c Nongkhai Hospital   (Thailand)

^d Mahasarakham Hospital   (Thailand)

Author keywords

Burkholderia pseudomallei; HMGB1; Melioidosis; Sepsis

Indexed keywords

CEFTAZIDIME; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADJUVANT THERAPY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELIOIDOSIS; MOUSE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEPTICEMIA; SURVIVAL; SURVIVAL RATE; AGED; ANIMAL; BACTEREMIA; BAGG ALBINO MOUSE; BLOOD; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BIOMARKERS; CEFTAZIDIME; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MELIOIDOSIS; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84907954238     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.07.025     Document Type: Article

References (27)

1. Yang H., Tracey K.J. High mobility group box 1 (HMGB1). Crit Care Med 2005, 33:S472-S474.
2. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
3. Yang H., Wang H., Czura C.J., Tracey K.J. The cytokine activity of HMGB1. J Leukoc Biol 2005, 78:1-8.
4. Riedemann N.C., Guo R.F., Ward P.A. Novel strategies for the treatment of sepsis. Nat Med 2003, 9:517-524.
5. de Jong H.K., van der Poll T., Wiersinga W.J. The systemic pro-inflammatory response in sepsis. J Innate Immun 2010, 2:422-430.
6. Wang H., Zhu S., Zhou R., Li W., Sama A.E. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 2008, 10:e32.
7. Mackenzie I., Lever A. Management of sepsis. BMJ 2007, 335:929-932.
8. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., et al. Reversing established sepsis with antagonist of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004, 101:296-301.
9. Suda K., Kitagawa Y., Ozawa S., Saikawa Y., Ueda M., Ebina M., et al. Anti-high-mobility group box chromosome protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006, 30:1755-1762.
10. Wiersinga W.J., van der Poll T., White N.J., Day N.P., Peacock S.J. Melioidosis: insights into pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006, 4:272-282.
11. Leelarasamee A. Recent development in melioidosis. Curr Opin Infect Dis 2004, 17:131-136.
12. Simpson A.J., Smith M.D., Weverling G.J., Suputtamongkol Y., Angus B.J., Chaowagul W., et al. Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis 2000, 181:621-625.
13. Lauw F.N., Simpson A.J., Prins J.M., Smith M.D., Kurimoto M., van Deventer S.J., et al. Elevated plasma concentrations of interferon (IFN)-gamma and IFN-gamma inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J Infect Dis 1999, 180:1878-1885.
14. Limmathurotsakul D., Wongrattanacheewin S., Teerawattanasook N., Wongsuvan G., Chaisuksant S., Chetchotisakd P., et al. Increasing incidence of human melioidosis in northeast Thailand. Am J Trop Med Hyg 2010, 82:1113-1117.
15. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. Surviving Sepsis Campaign.
16. Vincent J.L., de Mendonca A., Cantraine F., Moreno R., Takala J., Suter P.M., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1988, 26:1793-1800.
17. Lin Q., Fang J., Fang D., Li B., Zhou H., Su S.B. Production of recombinant human HMGB1 and anti-HMGB1 rabbit serum. Int Immunopharmacol 2011, 11:646-651.
18. Ulett G.C., Hirst R., Bowden B., Powell K., Norton R. A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model. J Antimicrob Chemother 2003, 51:77-81.
19. Boonma P., Bhuripanyo K., Sithikaesorn J., Patjanasoontorn B., Sookparnee M. Discriminant analysis among septicemic melioidosis and other bacterial septicemia. J Med Assoc Thai 1990, 73:543-547.
20. Wiersinga W.J., Calandra T., Kager L.M., van der Windt G.J., Roger T., le Roy D., et al. Expression and function of macrophage migration inhibitory factor (MIF) in melioidosis. PLoS Negl Trop Dis 2010, 4:e605.
21. Walsh A.L., Smith M.D., Wuthiekanun V., Suputtamongkol Y., Chaowagul W., Dance D.A., et al. Prognostic significance of quantitative bacteremia in septicemic melioidosis. Clin Infect Dis 1995, 21:1498-1500.
22. Panomket P., Chetchotisakd P., Sermswan R.W., Pannengpetch P., Wongratanacheewin S. Use of a low dose steroid as adjunctive treatment in mouse severe sepsis due to Burkholderia pseudomallei infection. Ann Trop Med Parasitol 2009, 103:635-646.
23. Fink M.P. Ethyl pyruvate: a novel treatment for sepsis and shock. Minerva Anestesiol 2004, 70:365-371.
24. Davé S.H., Tilstra J.S., Matsuoka K., Li F., DeMarco R.A., Beer-Stolz D., et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009, 86:633-643.
25. Ulloa L., Ochani M., Yang H., Tanovic M., Halperin D., Yang R., et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002, 99:12351-12356.
26. Charoensap J., Utisincharoens P., Engering A., Sirisinha S. Differential intracellular fate of Burkholderia pseudomallei 844 and Burkholderia thailandensis UE5 in human monocyte-derived dendritic cells and macrophages. BMC Immunol 2009, 10:20.
27. Sukumaran S.K., Shimada H., Prasadarao N.V. Entry and intracellular replication of Escherichia coli K1 in macrophages require expression of outer membrane protein A. Infect Immun 2003, 71:5951-5961.